Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sarepta Therapeutics (NQ: SRPT ) 127.97 +2.96 (+2.37%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sarepta Therapeutics < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments Today 16:05 EST From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 31, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results October 23, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights October 21, 2024 Via Benzinga Unveiling 15 Analyst Insights On Sarepta Therapeutics October 21, 2024 Via Benzinga Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics October 04, 2024 Via Benzinga Unveiling 26 Analyst Insights On Sarepta Therapeutics September 06, 2024 Via Benzinga This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday October 21, 2024 Via Benzinga After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent October 18, 2024 Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... Via Benzinga Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up October 18, 2024 The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. Via Investor's Business Daily 2 High-Flying Growth Stocks With Massive Upside Potential October 17, 2024 These innovative drugmakers have potential catalysts ahead. Via The Motley Fool Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics October 03, 2024 These two could become direct competitors relatively soon. Via The Motley Fool How Is The Market Feeling About Sarepta Therapeutics? August 16, 2024 Via Benzinga A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics August 15, 2024 Via Benzinga $100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today August 12, 2024 Via Benzinga Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 30, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher September 30, 2024 Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy Via MarketBeat Exposures Product Safety Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress September 26, 2024 From Sarepta Therapeutics, Inc. Via Business Wire 10 Health Care Stocks With Whale Alerts In Today's Session September 18, 2024 Via Benzinga Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors September 16, 2024 From Sarepta Therapeutics, Inc. Via Business Wire These 2 Biotech Stocks Are Set to Soar September 13, 2024 Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. Via The Motley Fool Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year September 05, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy September 03, 2024 Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... Via Benzinga Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building September 03, 2024 The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. Via Investor's Business Daily Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 30, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference August 30, 2024 From Sarepta Therapeutics, Inc. Via Business Wire This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now? August 19, 2024 Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. Via MarketBeat 2 Biotech Stocks to Buy Hand Over Fist in August August 12, 2024 Both of these biotechs are highly innovative companies. Via The Motley Fool Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? August 11, 2024 These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. Via Benzinga How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics August 09, 2024 The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
